Stay updated on PHA-022121 Dose Study for Acute Angioedema Clinical Trial
Sign up to get notified when there's something new on the PHA-022121 Dose Study for Acute Angioedema Clinical Trial page.

Latest updates to the PHA-022121 Dose Study for Acute Angioedema Clinical Trial page
- Check5 days agoChange DetectedThe footer revision label now reads v3.6.3, replacing the previous v3.6.2.SummaryDifference0.1%

- Check12 days agoChange DetectedThe revision history now includes a new latest revision entry (v3.6.2) and drops an older one (v3.6.0), reflecting an update to the page's version tracking. This preserves the historical record without altering study details.SummaryDifference0.1%

- Check19 days agoChange DetectedThis version removes multiple major sections from the study record view, including Arms and Interventions, Conditions, Study Description, Recruitment Status, and Study Design, across several dates. The deletions reduce visibility of core trial details in the public record.SummaryDifference14%

- Check26 days agoChange DetectedThe record indicates the study is no longer recruiting participants, marking a halt in enrollment. A new revision entry (v3.6.0) has been added to the history, replacing the prior revision (v3.5.5).SummaryDifference0.2%

- Check33 days agoChange DetectedThe record history now shows Revision: v3.5.5, replacing Revision: v3.5.4, indicating a new version of the page’s history. This update is a metadata/versioning change rather than a modification to trial data or content.SummaryDifference0.1%

- Check55 days agoChange DetectedThe record history shows a new revision label, Revision: v3.5.4, replacing the previous v3.5.3. This reflects a metadata update to the page’s revision history rather than changes to the study content or results.SummaryDifference0.1%

Stay in the know with updates to PHA-022121 Dose Study for Acute Angioedema Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PHA-022121 Dose Study for Acute Angioedema Clinical Trial page.